Larimar Therapeutics (LRMR) Free Cash Flow (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Free Cash Flow for 13 consecutive years, with -$23000.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Free Cash Flow rose 99.91% year-over-year to -$23000.0; the trailing twelve-month figure through Dec 2025 stood at -$46.0 million (up 35.48% YoY), and the FY2025 full-year result was -$113.3 million, down 58.86% from the prior year.
• Free Cash Flow climbed to -$23000.0 in Q3 2025 per LRMR's latest filing, from -$19.4 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$23000.0 in Q3 2025 and bottomed at -$26.6 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$11.6 million across 5 years, with a median of -$9.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 167.77% in 2024, then jumped 99.91% in 2025.
• Over 5 years, Free Cash Flow stood at -$7.9 million in 2021, then rose by 15.83% to -$6.7 million in 2022, then tumbled by 43.17% to -$9.6 million in 2023, then tumbled by 130.67% to -$22.0 million in 2024, then soared by 99.9% to -$23000.0 in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$23000.0, -$19.4 million, and -$26.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.